INTRODUCTION
Previous international reviews of prostate cancer epidemiology have reported high incidence in Western countries, with lower but typically increasing incidence in less developed countries [1] [2] [3] . These varying patterns have been partly attributed to the availability of screening using prostate-specific antigen (PSA) to detect asymptomatic tumours, and are also linked to a range of other issues such as diet, genetic, lifestyle and environmental factors [1, 2] . There is much uncertainty about the diagnosis and treatment of prostate cancer, with disputed interpretations of the benefits of PSA [4, 5] . Further-
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Data on survival were obtained from country-specific published reports where available. When presenting this information we acknowledge the limitations associated with comparing survival statistics across varying time periods, data quality, methodologies and clinical characteristics of the patients [17] . For this reason we have focussed more on the broad variation in survival across the Asian-Pacific countries rather than differences in the individual estimates [18] . These statistics were supplemented with the mortality:incidence rate ratio (MR:IR) to provide approximate estimates of survival for each country and to validate the general patterns. Low MR:IR (closer to zero) values indicate high survival, while high MR:IR (closer to one) values correspond to poor survival.
STATISTICAL METHODS
All incidence and mortality rates were directly age-standardised to the Segi World Standard population [19] . Rates are presented for males of all ages, as well as men aged 50 to 79 years, where possible, for consistency with previous studies [20, 21] . Trends in prostate cancer incidence and mortality were assessed using a statistical method called Joinpoint analysis [22] , which evaluates changing linear trends over successive segments of time. This methodology has been used in several previous studies that assessed changes in population-based trends in prostate cancer incidence or mortality [1, 3, 21, [23] [24] [25] . A joinpoint can be considered as the point at which the linear trend changes significantly in terms of either direction or magnitude. To reduce the chance of reporting trends that were due to random fluctuations, we set a minimum of six years between a joinpoint and either end of the data series, with at least four years of data between joinpoints and a maximum of three joinpoints allowed.
PROSTATE CANCER INCIDENCE
Worldwide, nearly 900,000 men (33 per 100,000 population) were estimated to have been diagnosed with prostate cancer during 2008 (Table 1) . About 14% (122,000) were diagnosed within the Asia-Pacific region (10 per 100,000), with three out of every four of these prostate cancer cases diagnosed in either Japan (32%), China (28%) or Australia (15%). Incidence rates varied by almost 50-fold across the region, ranging from estimates of between 2 to 3 per 100,000 in North Korea and Mongolia up to 100 per 100,000 in New Zealand and 105 per more, unlike most other types of cancer, there is no definitive recommendation about the optimum management of this disease once it is diagnosed [6] .
The purpose of this study was to examine and compare data on incidence, mortality and survival for countries in the Asia-Pacific region, based on the subregions of Eastern Asia, South-Eastern Asia and Oceania as defined by the World Health Organization [7] . This area comprises about 32% of the world's male population [8] and includes many nations whose populations are increasing rapidly. With its very heterogeneous mix of cultures, populations and economies, from powerhouses such as Japan, China and Singapore to poorer economies typified by those of Laos and Cambodia, the Asia-Pacific region provides an ideal opportunity to explore these variations together with changing patterns, trends and influences on prostate cancer epidemiology across the different environments.
DATA SOURCES
GLOBOCAN is a database constructed by the World Health Organization (WHO) which contains country-specific estimates of cancer incidence in 2008 for different types of cancer. Data quality within GLOBOCAN varies greatly, from accurate national information obtained from population-based cancer registries to estimates obtained by applying age-specific rates from neighbouring countries. We extracted incidence and mortality estimates for the countries listed in Table 1 , in addition to totals for the WHO subregions of Eastern Asia, SouthEastern Asia and Oceania.
Annual incidence data used in trend calculations were obtained from either online sources (Country/Cancer Registry statistics or reports [9] [10] [11] [12] , Cancer Incidence in Five Continents plus [13] ), or through contacting individual cancer registries and data custodians (Ministry of Health, New Zealand [14]; Central Cancer Registry, South Korea [15] ). Data were obtained by year of diagnosis as either age-standardised incidence rates, or age-specific incidence counts and populations.
Country-specific mortality statistics by individual year are reported by the WHO in the Statistical Information System Mortality Database [16] . Since this database contains only actual data provided by countries, rather than estimated data, there was a smaller list of countries for which mortality trend data was available compared to GLOBOCAN. Furthermore, to enable meaningful analysis, Asia-Pacific countries were only included in our analysis if they had a minimum of 10 years data available and at least 100 prostate cancer deaths each year (averaged over the most recent 5 year period). Un- Data from GLOBOCAN [7] , United Nations Population Division [8] ASR, age standardised rate per 100,000 population, based on the Segi World Standard Population [19] .
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.12014 100,000 in Australia. Prostate cancer incidence rates increased with age. In Australia and New Zealand, incidence rates rose sharply after 50 years of age, while in some Asian countries (Japan, Hong Kong, and South Korea) the increase was more pronounced after 60 years of age (Fig. 1) .
Prostate cancer was the sixth most frequently diagnosed cancer among males during 2008 in the Asia-Pacific region, behind cancers of the lung, stomach, liver, colorectum and oesophagus [7] . This pattern was mainly driven by Eastern Asia, and in particular China, which represents about 62% of the region's male population [8] . However, prostate cancer was the most common male cancer in many parts of Oceania, including Australia, Fiji, New Caledonia and New Zealand, while it ranked second in Brunei, Micronesia, Polynesia and Rates were age-standardised to the Segi World Standard Population [19] , and expressed per 100,000 males. Singapore data was only available for residents of Chinese ethnicity (who comprise the majority of the population but have slightly higher rates of prostate cancer than Malay or Indian residents). Singapore data was only available for residents of Chinese ethnicity (who comprise the majority of the population but have slightly higher rates of prostate cancer than Malay or Indian residents).
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PROSTATE CANCER MORTALITY
More than a quarter of a million men (7 per 100,000) were estimated to have died from prostate cancer globally during 2008, including approximately 42,000 deaths (16%) in the Asia-Pacific region at a rate of 3 per 100,000 (Table 1) . China accounted for 34% of prostate cancer deaths within the region, followed by Japan (24%) and Indonesia (16%). There was considerable variation in the age-standardised mortality rate for prostate cancer, with mortality in the Oceania subregion 6 times greater than in Eastern Asia, and 3 times greater than in South-Eastern Asia. New Caledonia had the highest countryspecific mortality rate in the Asia-Pacific region of 45 deaths per 100,000, however absolute numbers were relatively low.
Prostate cancer accounted for about 2% of all cancer-related deaths in the Asia-Pacific region, ranking eighth compared to deaths due to other types of cancer [7] . However, it was the most common cause of cancer-related deaths in New Caledonia (26%) and the second most common in Australia (15%), New Zealand (14%), Fiji (12%), and Polynesia (10%) [7] .
There were recent, significant decreases in prostate cancer mortality of about 2% per year for males of all ages in Australia (1998 to 2006), Japan (2004 to 2010) and New Zealand (1995 to 2008) (Fig. 3, Table 3 ). In contrast, mortality rates have increased in other countries, by about 1% per year in Singapore (Table 3) .
PROSTATE CANCER SURVIVAL
There was a large disparity in the survival prospects of men with Fig. 3 . Prostate cancer mortality rate trends by age for selected Asian-Pacific countries, 1980-2010. Y-axis is shown on a log scale and expressed per 100,000 males. Rates were age-standardised to the Segi World Standard Population [19] . Data from World Health Organization Mortality Database [16] . Population data for the Philippines and Thailand was obtained from the United Nations [8] . Rates were directly age-standardised to the Segi World Standard Population [19] .
c)
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prostate cancer throughout the Asia-Pacific region (Table 4) . Five-year relative survival estimates of 85% and above were reported in New Zealand, Australia, Japan, Singapore and South Korea. This contrasts with estimated 5-year survival rates of between 30% to 40% in parts of China and Thailand. Further evidence supporting these differences in survival is gained from the MR:IR ratio, as shown in Fig. 4 One of the main prognostic factors for prostate cancer is the stage (or extent and spread) of the disease at diagnosis, with survival outcomes much higher for men diagnosed with localised disease compared with advanced disease. For example in Japan, 5-year relative survival varied from close to 100% for localised disease to 87% for regional disease (cancer that had grown beyond the original tumour to nearby lymph nodes or organs and tissues) and 40% in cases where the cancer had spread to distant lymph nodes or organs [11] . This compares with corresponding 5-year survival estimates from Singapore of 83%, 43% and 23% for localised, regional and distant prostate cancer, respectively [26] . For prostate cancers diagnosed 5-year relative survival estimates were categorised to avoid over-interpretation of differences between country estimates, and defined as follows based on rounded estimates: High, ≥85%; medium, 50% to 84%; low, <50%. Fig. 4 . Prostate cancer incidence, mortality and mortality rate:incidence rate ratio (MR:IR) for Asian-Pacific countries, 2008. Rates were age-standardised to the Segi World Standard Population and expressed per 100,000 males [19] . MR:IR ratio categories were defined based on quintiles. Incidence categories were approximate quintiles, while mortality matched the incidence categories to enable comparison. Data from GLOBOCAN [7] . 
VARIATION IN PROSTATE CANCER INCI-DENCE BETWEEN COUNTRIES
A recent review of the burden of cancer in South East Asian nations [27] did not rank prostate cancer within the seven most important cancers. In contrast, prostate cancer was the most common invasive cancer in Australia and New Zealand [7] . The much lower incidence of prostate cancer in many countries in the Asia-Pacific region compared with more Westernised countries such as Australia and New Zealand may reflect differences in the prevalence of risk factors, such as genetic predisposition, diet, lifestyle or environment, and/ or it may be as a result of differing utilisation of screening through PSA testing. Of note is that the higher rates in Australia compared with New Zealand differ from those recently reported by Center and colleagues for 2000-2004 [3] reflecting the differing recent trends in these two countries. It is unclear whether genetics has a major role, with studies showing that Asians living in the United States have higher incidence rates of prostate cancer than the average rates of Asians living in their native countries, however incidence rates among Asian Americans are still much lower than nonHispanic White Americans [28] . These and other migrant studies [29, 30] that show consistently higher risks of prostate cancer among immigrants and their descendants suggest that the Western lifestyle, particularly in relation to diet, plays an important role in the aetiology of prostate cancer [25] .
Another contributing cause of international variation is likely to be the differing prevalence of PSA testing, where the aim is to detect prostate cancer. The increased use of PSA testing can artificially inflate the observed prostate cancer incidence rate because it detects latent, slow growing cancers that may not have become symptomatic otherwise. Therefore it is highly possible that, with lower rates of PSA testing in many Asian countries compared with Australia and New Zealand, much of the observed differential in prostate cancer incidence rates throughout the Asia-Pacific region may be due to differences in PSA testing [2] . Ironically, this contrasts completely in relation to the impact of the implementation of screening for cervical cancer through Pap smear testing, where the intention is to detect precancerous lesions, thus reducing the cancer incidence rate. Cervical cancer is the second most diagnosed cancer in South East Asia, and the third most common cause of cancer deaths, which has been linked in part to a lack of screening [27] .
Unfortunately there are only limited data on the prevalence of PSA testing or screening across these countries. In Queensland (Australia) in 2004, 52% of men aged 50 to 75 years reported to have ever had a PSA test [31] , while the annual rate of PSA testing in Australia in 2008/09 was between 21,000 and 25,000 tests per 100,000 men (21-25%) aged 50 to 79 years [23] . New Zealand had similar proportions, with 49% of men aged 40 to 74 years reporting having ever had a PSA test, and 22% within the previous 5 years [32] . In Japan the percentage of men over 50 years of age who received PSA screening was estimated to be less than 20% [33] . In South Korea only 15% of men aged over 50 in 2004 reported having been screened during the previous 2 years [34] .
However, much of the evidence for limited PSA testing is anecdotal, and based on the stage at which prostate cancers are diagnosed. Since PSA testing aims to detect asymptomatic cancers, it follows that countries with high proportions of prostate cancers that are localised would be more likely have higher rates of PSA testing. There have been calls for increases to PSA testing in several Asia Pacific countries because most of the prostate cancers detected are well advanced with poor prognoses [2, 35, 36] . Prostate cancer in Malaysia and rural China is typically a disease diagnosed at a more advanced stage at diagnosis [35, 36] . In Malaysia, for example, one institutional study found over half of prostate cancers were already at Stage 4 [36] compared with less than 20% in Japan [11] . This was also evidenced in the data we have presented, with higher rates of 5-year survival and much lower values for MR:IR in Australia, New Zealand, and Japan compared to many other countries in the Asia-Pacific region.
INCREASING PROSTATE CANCER INCIDENCE
In addition to the wide variations in incidence rates across countries, the epidemiology of prostate cancer in the AsiaPacific region is characterised by a generally increasing incidence burden, something also seen in many northern and western European countries [3] . There are several potential explanations for this trend in the Asia-Pacific region.
While the exact causes of prostate cancer are unclear, as already mentioned there is suggestive evidence for an impact of Western lifestyle. Many countries in the Asia-Pacific have experienced a shift from traditional high fibre and carbohydrate diets based on vegetable foods to a westernised diet that centres around red or processed meat with high total and satu-
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As our results demonstrate, the majority of prostate cancer cases are diagnosed between 50-79 years of age. The age distribution of a population therefore has a major influence on the absolute numbers of men diagnosed with prostate cancer. Given that life expectancy is expected to increase markedly in many parts of Asia over coming years [27, 40, 41] , the burden of prostate cancer in this region is likely to be a high priority in the future [42] .
PSA testing is also likely to have an important influence on the increasing incidence of prostate cancer. As prostate cancer becomes more common it leads to greater public awareness, which in turn prompts asymptomatic men to request PSA testing while also stimulating general practitioners to utilise it as a screening tool [41] . Indeed, the increasing incidence of prostate cancer in Singapore has been suggested to be due to more widespread, although still ad hoc, use of PSA testing [40] .
At the same time, it is increasingly recognised that testing of asymptomatic men with the PSA test is resulting in over diagnosis of the disease due to the detection of cancers that are not clinically significant [43] , prompting one commentator to note that "limiting the extent of PSA testing would be one of the means to reduce the prevalence of prostate cancer" [44] . While this may hold some truth, mortality rates are also increasing in several countries in the Asia-Pacific along with increasing incidence rates, which suggests that at least some of the increasing incidence is related to tumours that have the capacity to progress.
VARIATION IN PROSTATE CANCER MORTALITY TRENDS BETWEEN COUNTRIES
Stark differences in prostate cancer mortality trends in the Asia-Pacific region were found between more developed countries (Australia, New Zealand, and Japan), where mortality has begun to significantly decrease, as opposed to less developed countries such as the Philippines and Thailand where large increases in mortality over recent years have been observed.
The reasons for this variation are likely to be multifaceted. Refinements to treatment and management of early stage prostate cancers [45] and easier access to these treatments in more developed countries would be one of the main drivers. PSA testing may also be involved in terms of increasing the proportion of cases where the disease is treatable [46] , although opinion remains divided on the ability of screening to reduce mortality [4, 5] . The fact that incidence rates are generally continuing to increase in those countries where mortality rates are decreasing suggests against a change in the prevalence of risk factors for prostate cancer being a contributing element [47] .
CONCLUSION
Prostate cancer in the Asia-Pacific region is characterised by wide variations in incidence and mortality, combined with evidence of an increasing burden of incidence in many areas. The lack of population-based data across most of the countries in this region limits the ability of researchers to understand and report on the patterns and distribution of this important cancer. Potential solutions will require a long-term commitment, and involve the implementation of registration and reporting mechanisms that currently may not be feasible. However governments and health planners typically require quantitative evidence as a motivation for change. Unless there is a widespread commitment to improve the collection and reporting of data on prostate cancer, including the provision of international assistance, it is likely that the burden of prostate cancer will continue to increase. Enhancing knowledge transfer from country to country where there are differentials in capacity, policy and experience may provide the necessary impetus and opportunity to overcome at least some of the existing barriers.
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